For sales

This World Parkinson’s Day, we stand united to amplify awareness and drive meaningful change. Parkinson’s is more than a condition—it’s a journey that impacts millions of lives. By supporting research, innovation, and compassionate care, we move one step closer to a better future. Together, let’s turn awareness into action.

World Parkinson’s Day 2026 Substantia nigra (Dopamine producing cells) Dopamine levels in normal neuron Parkinson’s disease (PD) is a neurodegenerative disorder that predominantly affects the dopamine-producing “dopaminergic” neurons, in specific area of the brain called the substantia nigra Lewy body inclusion Diffuse α-synuclein aggregates Motor Neuron Receiving neuron Transmitting neuron Dopamine receptor Dopamine Cellular Pathology Oligomerization α-synuclein monomer Mature Lewy body inclusion α-synuclein protofibril oligomer α-synuclein fibril aggregates Autocatalytic process Dopamine levels in PD affected neuron High PD symptoms Non-motor symptoms Motor symptoms 25.2M people with PD disease globally by 2050 Depression, anxiety, cognitive impairment Low Stooped posture Masked face Back rigidity Forward tilt Flexed elbows and wrists Loss of smell Prevalence of PD in the US Hand tremor Gastrointestinal symptoms M Flexed hip and knees W Tremors in legs 1.2M (2030) Americans will be living with PD 54% 46% 80+ 60-79 40-59 Joint pain Shuffling, short stepped gait (Age 80+) Age groups Clinical symptoms and time course of PD progression Early stages PD Diagnosis Advanced stages Prodromal period Impaired balance, functioning intact Both sides affected but balance remains One side of the body is affected Constipation RBD Walking and standing difficult without help Wheelchair-bound or bed-ridden -10 0 -20 10 20 PD management Diagnosis Symptomatic Treatment No Disease-modifying therapies (DMT) approved HIGH UNMNET NEED PERSISTS MAO-B inhibitors (MAOBi): Rasagiline, Selegiline Levodopa-Carbidopa: Standard fixed dose Prodrug formulations: Foslevodopa/ Foscarbidopa MRI PET scan SNCA LRRK2 GBA Blood & CSF Biomarkers MDS-UPDRS PDQ-39 "ON/OFF" Time Deep-Brain Stimulation (DBS) DBS for stronger symptom relief Neuroimaging Assessments Genetic tests Laboratory tests Vyuhgenics®, ISO 27001 & 9001 certified Note: This report is generated based on publicly available data
Download

Connect with us

Please fill in the information below, and we'll get back to you.